https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-01-26 / Cancer Immunol. Immunother. 2012 Sep;61(9):1407-13
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-01-26 / Cancer Immunol. Immunother. 2012 Sep;61(9):1407-132012-01-26 00:00:002019-02-15 08:48:05Quality of life during dendritic cell vaccination against metastatic renal cell carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-10-20 / J Transl Med 2011 Oct;9:178
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-10-20 / J Transl Med 2011 Oct;9:1782011-10-20 00:00:002019-02-15 08:50:33Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-10-01 / Expert Rev Vaccines 2011 Oct;10(10):1355-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-10-01 / Expert Rev Vaccines 2011 Oct;10(10):1355-72011-10-01 00:00:002019-02-15 08:53:13Proving the principle: dendritic cell-based vaccines in urogenital cancers
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-04-20 / PLoS ONE 2011 Apr;6(4):e18801
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-04-20 / PLoS ONE 2011 Apr;6(4):e188012011-04-20 00:00:002019-02-15 08:53:13Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-10-22 / BMC Cancer 2010 Oct;10:578
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-10-22 / BMC Cancer 2010 Oct;10:5782010-10-22 00:00:002019-02-15 08:48:06Chemokine-mediated distribution of dendritic cell subsets in renal cell carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-05-01 / J. Immunother. 2010 May;33(4):425-34
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-05-01 / J. Immunother. 2010 May;33(4):425-342010-05-01 00:00:002019-02-15 08:48:07Increase of circulating CD4+CD25highFoxp3+ regulatory T cells in patients with metastatic renal cell carcinoma during treatment with dendritic cell vaccination and low-dose interleukin-2
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-11-01 / Scand. J. Immunol. 2009 Nov;70(5):481-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-11-01 / Scand. J. Immunol. 2009 Nov;70(5):481-92009-11-01 00:00:002019-02-15 09:16:49Immune responses in patients with metastatic renal cell carcinoma treated with dendritic cells pulsed with tumor lysate
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-09-01 / Int. J. Oncol. 2009 Sep;35(3):569-81
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-09-01 / Int. J. Oncol. 2009 Sep;35(3):569-812009-09-01 00:00:002019-02-15 08:48:08Massive expansion of regulatory T-cells following interleukin 2 treatment during a phase I-II dendritic cell-based immunotherapy of metastatic renal cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-04-10 / Cancer Immunol. Immunother. 2009 Jul;58(7):1169-74
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-04-10 / Cancer Immunol. Immunother. 2009 Jul;58(7):1169-742009-04-10 00:00:002019-02-15 08:48:09Vaccination strategies in patients with renal cell carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-02-17 / Cancer Immunol. Immunother. 2009 Oct;58(10):1587-97
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-02-17 / Cancer Immunol. Immunother. 2009 Oct;58(10):1587-972009-02-17 00:00:002019-02-15 09:16:51Patient-derived renal cell carcinoma cells fused with allogeneic dendritic cells elicit anti-tumor activity: in vitro results and clinical responses
